This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. 
S1: Further details of recruitment
Participants aged 16 years and over were recruited from 54 different NHS centres and community settings located in London, Leicester and Birmingham. Participants were recruited from healthcare, work and community settings including places of worship, schools/colleges and workplaces if they were: (a) close contacts of cases of active TB or (b) migrants arriving in the last 5 years from high incidence countries defined as exceeding 40 per 100,000 and operationalised by focussing on those from sub-Saharan Africa or Asia. Eligible persons were identified by study TB specialists or Practice Nurses and written informed consent obtained following provision of information sheets (translated as appropriate). GPs of all participants were informed of their patients' participation by letter.
At the time of the study, treatment of LTBI was recommended only for individuals aged under 35 years. We therefore prioritised the recruitment of patients aged >35 years (not eligible for chemoprophylaxis) in order to estimate and compare the ability of TST and IGRA tests to predict natural progression to active disease. Individuals aged 16-34 were also eligible, as they may not be offered, or may not accept, chemoprophylaxis.
Recruitment of contacts
In the UK, individuals who have been in contact with a patient with active TB are invited to attend a TB clinic to be screened for active disease and latent infection. Contacts of all active TB (pulmonary and extra-pulmonary) patients, attending participating TB clinics for screening were invited to take part in the PREDICT study. Contacts included all individuals with a cumulative duration of exposure of greater than eight hours to the relevant index case in a confined space during the period of infectiousness (prior to initiation of treatment).
Additionally, in some situations contacts of active cases were recruited through mass screening events organised as part of the public health response to a case of active TB. For example, clinical teams may attend workplaces or colleges where an exposure has taken place, to facilitate screening of large numbers of contacts.
Recruitment of migrants
Migrants to the UK from high incidence countries were identified through primary care and through community events.
For recruitment through primary care, study flyers and the contact details of the coordinating centre were displayed in GP surgeries so that interested people could contact the study team. At the appointment, as with all recruitment meetings, a research nurse went through the full patient information leaflet before taking written informed consent to undertake study procedures. We also utilised the PCT-held Flag4 data (records held by the local primary care group about international migrants who register with an NHS GP) to invite newly registered patients, recently arrived from the countries of interest, to take part in the study.
Migrants were also recruited from community settings on non-NHS premises, such as places of worship and community centres.
In addition to recruiting participants who had recently come to the UK, individuals born in high incidence countries who entered the UK more than five years ago, but who had spent more than one year (cumulative) in the past five years in a high incidence country as per the study's defined list, were also eligible to participate.
S2: Case definitions for active TB
Individuals were considered to have progressed to active TB if they had culture confirmed TB or were clinically diagnosed with radiological or histological evidence of TB and a clinician had decided to treat the individual with a full course of anti-TB disease treatment, the definition used for the TB register. In addition, participants were considered to have progressed to TB only if:
-
The participant had no evidence of active TB at the time of enrolment determined through the review of clinical records.
The clinical diagnosis of active TB was at least 21 days after recruitment/enrolment to the PREDICT study, based on the date of diagnosis (or treatment start date if date of diagnosis was not available). The study steering committee discussed and agreed 21 days in view of the delays before first appointment and likely higher chance of early progression that will be excluded with a longer time window.
In the absence of laboratory confirmation of TB, awareness by the clinician of a prior positive IGRA/TST result should not influence the clinical diagnosis of active TB. Any case that was subsequently denotified (i.e. where the clinician reported that the patient did not have TB) was not considered a progression.
If a participant self-reported a diagnosis of active TB in the follow-up phone call at 12 or 24 months, the national dataset of clinical reports and local hospital records were searched to confirm the diagnosis.
S3: Statistical model and additional details of sample size calculation
Poisson regression models were used for analyses of incidence rates accounting for variation in Regression models were fitted in STATA V15.0.
The study size (and associated power) was determined by simulating the study and its analysis 1000 times and observing the proportion of simulations yielding significant results across various scenarios.
The disease progression of simulated study participants data were created presuming a LTBI prevalence of 30% and 5% of participants with LTBI progressing to active TB in 2 years if untreated, as observed in previous studies 10, 23 . Test results were simulated for each participant using sensitivities and specificities of IGRA ranging between 65% and 95%. The simulations indicated that a cohort of 5,000 participants amongst whom 90 incident events would be expected to be observed would have around 85% power to detect significant (P<0.05) differences in predictive performance that would arise from differences in sensitivity and specificity of 10% between tests. These differences correspond to increases in predictive performance (expressed as a ratio of relative rates between test positives) of 30%, which would be clinically useful. 95% CI (4.4, 11.4) (3.8, 10.5) (4.4, 11.5) (4.5, 11.7) *Using the 6,520 participants now with all test results but excluding participants who were non UK born and initially assumed to be BCG vaccinated. 
S4. Detailed test results

